A CYP17A1 inhibitor
Related Products
Active Metabolite(s)
9002768Abiraterone 27594Δ4-Abiraterone
Labeled Version(s)
22096Abiraterone Acetate-d4
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Abiraterone Acetate

Item No. 15148

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3β)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol, acetate ester
CAS Number
154229-18-2
Synonyms
  • CB-7630
Molecular Formula
C26H33NO2
Formula Weight
391.6
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 16 mg/mlDMSO: 2 mg/mlEthanol: 16 mg/mlEthanol:PBS (pH 7.2)(1:2): 0.3 mg/ml
λmax
254 nm
SMILES
C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5
InChi Code
InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1
InChi Key
UVIQSJCZCSLXRZ-UBUQANBQSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $134

    Add

    10 mg

    $202

    Add

    25 mg

    $432

    Add

    50 mg

    $729

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Abiraterone acetate is an inhibitor of the cytochrome P450 (CYP) isoform CYP17A1 (IC50s = 17 and 18 nM for inhibition of C17,20-lyase and 17α-hydroxylase activities, respectively).1 It is also a prodrug form of abiraterone (Item No. 9002768).2 Abiraterone acetate reduces plasma testosterone levels, increases plasma luteinizing hormone levels, and reduces ventral prostate, seminal vesicle, testis, and kidney weight in mice when administered at doses of 0.1 and 0.5 mmol/kg per day. It also reduces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in the culture supernatant of infected Vero E6 cells (EC90 = 8.4 μM) and is active in a plaque reduction assay (EC50 = 1.94 μM).3 Formulations containing abiraterone acetate have been used in combination therapy for the treatment of metastatic castration-resistant prostate cancer.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Potter, G.A., Barrie, S.E., Jarman, M., et al. Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. J. Med. Chem. 38(13), 2463-2471 (1995).

    2. Barrie, S.E., Potter, G.A., Goddard, P.M., et al. Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 50(5-6), 267-273 (1994).

    3. Yuan, S., Chan, J.F.W., Chik, K.K.H., et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol. Res. 159, 104960 (2020).